➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
Merck
AstraZeneca
Moodys

Last Updated: October 21, 2021

DrugPatentWatch Database Preview

xhance Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Xhance, and when can generic versions of Xhance launch?

Xhance is a drug marketed by Optinose Us Inc and is included in one NDA. There are fourteen patents protecting this drug.

This drug has two hundred and seventy-one patent family members in twenty-eight countries.

The generic ingredient in XHANCE is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Xhance

A generic version of xhance was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.

  Try it Free

US Patents and Regulatory Information for xhance

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for xhance

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Try it Free ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Try it Free ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Try it Free ⤷  Try it Free
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for xhance

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1519731 92269 Luxembourg ⤷  Try it Free PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1305329 SPC/GB08/026 United Kingdom ⤷  Try it Free PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
2506844 2018C/022 Belgium ⤷  Try it Free PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
2506844 1890025-8 Sweden ⤷  Try it Free PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
1305329 08C0014 France ⤷  Try it Free PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
Merck
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.